Page 2 - CUAJ Dec. 2022
P. 2
®
KEYTRUDA
HAS A NEW INDICATION
Dear Healthcare Providers,
We are pleased to inform you that KEYTRUDA is now indicated for adjuvant treatment,
®
as monotherapy, of adult patients with RCC at intermediate-high or high risk of recurrence
following nephrectomy, or following nephrectomy and resection of metastatic lesions.
SEE KEYNOTE-564 TRIAL RESULTS
SCAN THE QR CODE TO LEARN MORE
Consult the Product Monograph at https://www.merck.ca/static/pdf/KEYTRUDA-PM_E.pdf for
important information relating to contraindications, warnings, precautions, adverse reactions,
interactions, dosing, and conditions of clinical use. The Product Monograph is also available by
calling us at 1-800-567-2594.
Sincerely yours,
Amy Klug
Executive Director, Oncology
Merck Canada Inc.
® Merck Sharp & Dohme LLC. Used under license.
© 2022 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. CA-RCC-00065
186-2929-[MERCK] RCC NOC Annoucement - PDF V4.indd 1 2022-09-12 12:45 PM